RAF265 (CHIR-265) is primarily used in cancer research due to its ability to inhibit both RAF kinase and VEGFR2. This dual inhibition makes it a potential candidate for targeting tumors that rely on the RAF/MEK/ERK signaling pathway, which is often dysregulated in various cancers. By blocking these pathways, it can suppress tumor growth and angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. Researchers are exploring its efficacy in treating melanoma, colorectal cancer, and other solid tumors. Additionally, its role in preclinical studies helps in understanding the molecular mechanisms of cancer progression and resistance to therapy.